Please wait a minute...
 Home  Journals Subscription Open Access About Us
中文
 
Just Accepted  |  Online First  |  Current Issue  |  Archive  |  Special Issues  |  Featured Articles  |  Most Downloaded
Journal of Translational Neuroscience    2016, Vol. 1 Issue (1) : 27-31     DOI: 10.3868/j.issn.2096-0689.01.004
Review |
Advancements in pathogenesis studies of Rasmussen's encephalitis
Sichang Chen1,2,3, Shuai Chen1,2,3, Yuguang Guan1,2,3, Xueling Qi1,2, Guoming Luan1,2,3*
1. Department of Neurosurgery,Beijing Sanbo Brain Hospital, Capital Medical University, Beijng 100093, China;
2. Beijing Key Labartory of Epilepsy, Beijing 100093, China;
3. Center of Epilepsy,Beijing Institute for Brain Disorders, Beijing 100069, China
Download: PDF(108 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Guide   
Abstract Rasmussen's encephalitis (RE), which was first described by Rasmussen in 1958, is a rare, dispersed, and progressive neurological syndrome that is characterized by focal epilepsy, unilateral inflammation of the cerebral cortex, progressive hemiplegia and cognitive deterioration. The etiology of this syndrome remains under investigation, and it is hypothesized and widely accepted that RE is a T-cell-mediated autoimmune response. However, the antigenic epitopes and mechanisms are still unknown. The pathological characteristics of RE are cortical inflammation, neuronal loss, and gliosis that are confined to one cerebral hemisphere. Hemispherectomy remains the only cure for the seizures and cognitive deterioration associated with the disease, but this procedure results in inevitable functional loss in the brain. Compared with surgery, immunomodulatory treatments are expected to cause less neurological deficits, but with limited clinical effect.
Keywords Rasmussen’s encephalitis(RE)      seizures      neuron degeneration      autoantibodies      T-cell cytotoxicity     
PACS:     
Fund: 
Corresponding Authors: *Guoming Luan, E-mail:luangm3@163.com   
Issue Date: 14 October 2016
 Cite this article:   
Sichang Chen,Yuguang Guan,Xueling Qi, et al. Advancements in pathogenesis studies of Rasmussen's encephalitis[J]. Journal of Translational Neuroscience, 2016, 1(1): 27-31.
 URL:  
http://journal.hep.com.cn/jtn/EN/10.3868/j.issn.2096-0689.01.004
http://journal.hep.com.cn/jtn/EN/Y2016/V1/I1/27
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Sichang Chen
Yuguang Guan
Xueling Qi
Guoming Luan
[1] Rasmussen T, Olszewski J, Lloydsmith D. Focal seizures due to chronic localized encephalitis. Neurology, 1958, 8(6): 435-445.
[2] Walter GF, Renella RR. Epstein-Barr virus in brain and Rasmussen’s encephalitis. Lancet, 1989, 1(8632): 279-280.
[3] Power C, Poland SD, Blume WT,et al. Cytomegalovirus and Rasmussen’s encephalitis. Lancet, 1990, 336(8726): 1282-1284.
[4] Jay V, Becker LE, Otsubo H,et al.Chronic encephalitis and epilepsy (Rasmussen’s encephalitis): detection of cytomegalovirus and herpes simplex virus 1 by the polymerase chain reaction and in situ hybridization. Neurology, 1995, 45(1): 108-117.
[5] Li Y, Uccelli A, Laxer KD,et al. Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. J Immunol, 1997, 158(3): 1428-1437.
[6] Schwab N, Bien CG, Waschbisch A,et al. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain, 2009, 132(Pt 5): 1236-1246.
[7] Takahashi Y, Matsuda K, Kubota Y,et al. Vaccination and infection as causative factors in Japanese patients with Rasmussen syndrome: molecular mimicry and HLA class I. Clin Dev Immunol, 2006, 13(2-4): 381-387.
[8] Merkler D, Horvath E, Bruck W, et al. “Viral deja vu” elicits organ-specific immune disease independent of reactivity to self. J Clin Invest, 2006, 116(5): 1254-1263.
[9] McLachlan RS, Levin S, Blume WT. Treatment of Rasmussen’s syndrome with ganciclovir. Neurology, 1996, 47(4): 925-928.
[10] Atkins MR, Terrell W, Hulette CM. Rasmussen’s syndrome: a study of potential viral etiology. Clin Neuropathol, 1995, 14(1): 7-12.
[11] Eeg-Olofsson O, Bergstr m T, Andermann F,et al. Herpesviral DNA in brain tissue from patients with temporal lobe epilepsy. Acta Neurol Scand, 2004, 109(3): 169-174.
[12] Rogers SW, Andrews PI, Gahring LC,et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis. Science, 1994, 265(5172): 648-651.
[13] Bien CG, Bauer J, Deckwerth TL,et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen’s encephalitis. Ann Neurol, 2002, 51(3): 311-318.
[14] He XP, Patel M, Whitney KD, et al.Glutamate receptor GluR3 antibodies and death of cortical cells. Neuron, 1998, 20(1): 153-163.
[15] Levite M, Fleidervish IA, Schwarz A,et al. Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. J Autoimmun, 1999, 13(1): 61-72.
[16] Yang R, Puranam RS, Butler LS,et al. Autoimmunity to munc-18 in Rasmussen’s encephalitis. Neuron, 2000, 28(2): 375-383.
[17] Takahashi Y, Mori H, Mishina M,et al. Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology, 2003, 61(7): 891-896.
[18] Watson R, Jepson JE, Bermudez I,et al.Alpha7-acetylcholine receptor antibodies in two patients with Rasmussen encephalitis. Neurology, 2005, 65(11): 1802-1804.
[19] Takahashi Y, Yamazaki E, Mine J,et al. Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood. Brain Dev, 2013, 35(8): 778-785.
[20] Watson R, Jiang Y, Bermudez I,,et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology, 2004, 63(1): 43-50.
[21] Gahring L, Carlson NG, Meyer EL,et al. Granzyme B proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation. J Immunol, 2001, 166(3): 1433-1438.
[22] Bauer J, Bien CG, Lassmann H. Rasmussen’s encephalitis: a role for autoimmune cytotoxic T lymphocytes. Curr Opin Neurol, 2002, 15(2): 197-200.
[23] Takahashi Y, Mine J, Kubota Y,et al. A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFalpha, and Granzyme B in CSF. Epilepsia, 2009, 50(6):1419-1431.
[24] Osorio I, Shnyra A, Santacruz K,et al.Rasmussen’s encephalitis: interleukin-10-dependent Tc2 cell polarization may explain its pathophysiology and clinical course. Epilepsy Behav, 2007, 10(1): 206-211.
[25] Owens GC, Huynh MN, Chang JW,et al.Differential expression of interferon-gamma and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response. J Neuroinflammation, 2013,10: 56.
[26] Mirones I, de Prada I, Gómez AM,et al. A role for the CXCR3/CXCL10 axis in Rasmussen encephalitis. Pediatr Neurol, 2013, 49(6): 451-457.
[27] Ohmori I, Ouchida M, Kobayashi K,et al. Rasmussen encephalitis associated with SCN 1 A mutation. Epilepsia, 2008, 49(3): 521-526.
[28] Takahashi Y, Mogami Y, Mine J,et al.Genetic variations of immunoregulatory genes associated with Rasmussen syndrome. Epilepsy Res, 2013, 107(3): 238-243.
[29] Luan G, Gao Q, Guan Y,et al. Upregulation of adenosine kinase in Rasmussen encephalitis. J Neuropathol Exp Neurol, 2013, 72(11): 1000-1008.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
Copyright © 2014 Higher Education Press, All Rights Reserved. Powered by Beijing Magtech Co. Ltd
京ICP备12020869号-1 京ICP证150856号  京公网安备 11010202008535号
Service: 010-58556313 (Technology); 010-58556485 (Subscription) E-mail: subscribe@hep.com.cn